miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2
- PDF / 2,944,726 Bytes
- 9 Pages / 595.276 x 793.701 pts Page_size
- 13 Downloads / 218 Views
RESEARCH
Open Access
miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2 Mingxi Xu†, Meng Gu†, Ke Zhang†, Jun Zhou, Zhong Wang and Jun Da*
Abstract Background: Renal cell carcinoma (RCC) is one of the leading causes of cancer related mortality worldwide. Increasing evidence has shown that microRNAs function as oncogenes or tumor suppressors in human malignancies, but the roles of miR-203 in human RCC is still unclear. Methods: First, quantitative real-time PCR (qRT-PCR) was performed to detect miR-203 expression in renal cancer cell lines and clear cell RCC (ccRCC) specimens. Then, the association of miR-203 expression with clinicopathological features and survival was later analyzed. Finally, the roles of miR-203 in regulation of tumor proliferation, migration, invasion, and target gene expression were further investigated. Results: Our study showed miR-203 was down-regulated in renal cancer cell lines and ccRCC specimens (P < 0.05). Respectively, the low miR-203 expression in ccRCC specimens was associated with advanced clinical features and poorer prognosis (P < 0.05). miR-203 expression was an independent prognostic marker of overall ccRCC patient survival in a multivariate analysis (P < 0.05). Transient forced expression of miR-203 inhibited renal cancer cell growth and metastasis (P < 0.05). In contrast, down-regulation of miR-203 expression promoted renal cancer cell growth and metastasis (P < 0.05). Mechanistic investigations confirmed FGF2 as a direct target of miR-203, and up-regulation of miR-203 could decrease expression of FGF2. Further investigation showed that ectopic expression of FGF2 partially reversed the inhibition effect of enforced miR-203 expression on the malignant phenotypes of renal cancer cells. Conclusions: Our study suggested that miR-203 could be a potential prognostic marker and functions as a tumor suppressor in human renal cancer by post-transcriptionally targeting FGF2. Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/ 6828145701534108. Keywords: Renal cancer, miR-203, FGF2, Progression
Background Renal cell carcinoma (RCC) is the most common solid cancer of the adult kidney, accounting for approximately 90% of kidney neoplasms and 3% of all adult malignancies [1]. Worldwide mortality, as a result of RCC, currently exceeds 100,000 patients each year, with the incidence and mortality rate increasing by 2–3% per-decade [2]. Although radical nephrectomy is effective to cure early and local RCC, 20–40% of patients develop metastatic disease after surgery [3]. Patients with metastatic RCC face a dismal prognosis and have limited therapeutic * Correspondence: [email protected] † Equal contributors Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University, Shanghai 200011, China
options. Median survival in a recent cohort was only 1.5 years with fewer than 10% of patients surviving to 5 years [4]. Therefore, studying the molecular basis of RCC
Data Loading...
